6.15
-0.27(-4.21%)
Currency In USD
| Previous Close | 6.42 |
| Open | 6.4 |
| Day High | 6.59 |
| Day Low | 5.99 |
| 52-Week High | 14.26 |
| 52-Week Low | 4.31 |
| Volume | 1.09M |
| Average Volume | 1.55M |
| Market Cap | 546.09M |
| PE | -2.62 |
| EPS | -2.35 |
| Moving Average 50 Days | 6.92 |
| Moving Average 200 Days | 5.97 |
| Change | -0.27 |
If you invested $1000 in Verve Therapeutics, Inc. (VERV) since IPO date, it would be worth $192.67 as of March 13, 2025 at a share price of $6.15. Whereas If you bought $1000 worth of Verve Therapeutics, Inc. (VERV) shares 3 years ago, it would be worth $258.62 as of March 13, 2025 at a share price of $6.15.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
GlobeNewswire Inc.
Jan 29, 2025 12:00 PM GMT
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will
Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones
GlobeNewswire Inc.
Jan 13, 2025 12:00 PM GMT
Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in second quarter of 2025 Dosing in the Heart-2 trial has moved to the 0.6 mg/kg cohort VERVE-301 nominated as development candidate targeting the LPA gene; Ve
Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 08, 2025 12:00 PM GMT
BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will